The U.S. Food and Drug Administration has tentatively approved the generic version of Abacavir Sulfate Oral Solution for use by pediatric AIDS victims.
The pharmaceutical manufactured by Aurobindo Pharma LTD. of India, is the first generic version of the already approved Ziagen Oral Solution brand of abacavir manufactured by GlaxoSmithKline.
The 20mg pediatric formulation is indicated for use in pediatric patients from 3 months through 13 years of age who are HIV infected.
The agency's tentative approval of Aurobindo's abacavir solution means that although existing patents and exclusivity prevent marketing of the product within the United States, it meets all FDA quality, safety and efficacy standards for U.S. marketing.
The tentative approval will allow the generic drug to become available for consideration for purchase and use outside the United States under the President's Emergency Plan for AIDS Relief, the FDA said.
"Saving the lives of children with HIV is a foremost goal of PEPFAR," said Gary Buehler, the director of the FDA's Office of Generic Drugs. "The agency's action ... can help bring effective treatment to thousands of infected children, and thereby dramatically brighten their future."
Copyright 2006 by United Press International
Related stories:
Free drug samples may end up costing uninsured more
Free drug samples provided to physicians by pharmaceutical companies could actually be costing uninsured patients more in the long run, according to a study done by researchers at Wake Forest University Baptist Medical Center and colleagues.
Watch out for drug names that look, sound alike
(AP) -- Take the generic drug clonidine for high blood pressure? Double-check that you didn't leave the drugstore with Klonopin for seizures, or the gout medicine colchicine.
Sex differences seen in response to common antidepressant
Women with depression may be much more likely than men to get relief from a commonly used, inexpensive antidepressant drug, a new national study finds. But many members of both sexes may find that it helps ease their depression symptoms.
TiVo shows another profit, but outlook weak
(AP) -- TiVo Inc. posted a quarterly profit for only the third time in its 11-year history Wednesday as the pioneer in digital video recorders boosted margins on hardware and reduced marketing costs in its fiscal second quarter.
Potential diabetes treatment selectively kills autoimmune cells from human patients
In experiments using blood cells from human patients with diabetes and other autoimmune disorders, Massachusetts General Hospital (MGH) researchers have confirmed the mechanism behind a potential new therapy for type 1 diabetes. A team led by Denise Faustman, MD, PhD, director of the MGH Immunobiology Laboratory, showed that blocking a metabolic pathway regulating the immune system specifically eliminated immune cells that react against a patient's own tissues.
Intel CTO Says Gap between Humans, Machines will Close by 2050
Intel Corporation's chief technology officer took a fascinating look at how technology will bring man and machine much closer together by 2050.
Report says dietary supplements for horses, dogs and cats need better regulation
The growing use of animal dietary supplements has raised several concerns, including the safety of specific supplements and the approaches taken to determine their safeness. A new National Research Council report, requested by the Center for Veterinary Medicine of the U.S. Food and Drug Administration, assesses whether the addition of three dietary supplements -- lutein, evening primrose oil, and garlic -- to the diets of horses, dogs, or cats may cause significant adverse health effects.
Chemists make beds with soft landings
Bedsprings aren't often found in biology. Now, chemists have succeeded in making a layer of tiny protein coils attached to a surface, much like miniature bedsprings in a frame. This thin film made of stable and very pure helices can help researchers develop molecular electronics or solar cells, or to divine the biology of proteins.